Tax planning for dermatologists with mixed insurance and cash income

Insurance derm + cash aesthetics + Mohs = three different revenue streams with three different tax treatments. This isn’t just a clinical reality; it’s a financial one that creates massive complexity—and opportunity. As dermatologists, we operate at the intersection of medicine and retail, managing insurance-based procedural income alongside high-margin, direct-to-consumer cash services. This unique mix means generic “physician finance” advice often misses the mark entirely.

Most of us didn’t learn about EBITDA multiples, asset sales, or cost segregation studies in residency. We learned by seeing colleagues get a raw deal in a practice sale or by overpaying taxes for years without realizing it. The goal of this article is to arm you with the specific, actionable tax and operational strategies that apply directly to our field. These are the conversations you should be having with your financial team long before you ever think about selling. For a broader look at the operational side of our specialty, you can explore the full dermatology resources hub.

Structuring the PE Buyout: Asset Sale vs. Stock Sale

Private equity’s interest in dermatology isn’t slowing down. If you’re a practice owner, an offer is a matter of when, not if. When that letter of intent arrives, the headline number—the enterprise value—is designed to grab your attention. But the real money is made or lost in the fine print describing the transaction structure.

When I look at a deal sheet, the first thing I check is whether it’s an asset sale or a stock sale. The difference determines your after-tax take-home pay, and it can be a seven-figure swing.

• Asset Sale: The buyer purchases the individual assets of your practice (equipment, patient lists, goodwill, real estate) but not the legal entity itself. The PE firm loves this because they get a “step-up in basis” on the assets, allowing them to take larger depreciation deductions going forward. For you, the seller, it’s often a tax nightmare. The proceeds are allocated to different asset classes, and much of it—especially gain on depreciated equipment and goodwill—is taxed as ordinary income, at the highest marginal rates.
• Stock Sale: The buyer purchases the shares of your S-Corp or C-Corp. You are selling your ownership stake. For you, this is almost always preferable. The entire gain on the sale of your stock (held for more than a year) is typically taxed at the much lower long-term capital gains rate.

The trap is that most initial offers are structured as asset sales for the buyer’s benefit. Many physicians, focused on the top-line number, don’t realize the tax implications until it’s too late. Your counter-offer must address this directly. You can push for a stock sale, or if the buyer insists on an asset sale, you must negotiate a higher purchase price to compensate for your increased tax burden. This is a non-negotiable part of the deal. Don’t let anyone tell you otherwise.

Equity Rollover: Deferring Tax and Retaining Upside

In nearly every PE deal, you won’t walk away with 100% cash. The offer will be a mix of cash and “rollover equity”—stock in the new, larger entity created by the PE firm. For example, a $10 million valuation might be structured as $8 million in cash and $2 million in rollover equity.

Here’s how it works from a tax perspective: The cash portion is a taxable event in the year of the sale. The rollover equity portion, however, is generally tax-deferred. You don’t owe taxes on that $2 million of stock until a “second liquidity event” occurs, which is typically when the PE firm sells the entire platform to another, larger buyer 5-7 years down the road. This is often called getting a “second bite of the apple.”

The mechanics are governed by sections of the Internal Revenue Code (like §351 or §721) that allow for tax-free contributions of property to a corporation or partnership in exchange for stock. This deferral is powerful, but it comes with significant risks.

The Planning Trap: Not Understanding the New Capital Structure.
Most of us figured this out the hard way—by losing a year to a deal that fell apart over this exact issue. The equity you receive is not the same as the equity you sold. The PE firm will issue different classes of shares, and theirs (preferred equity) will have “liquidation preference.” This means they get their money out first in a future sale. If the new company sells for a disappointing price, it’s possible for the preferred shareholders to get paid while the common shareholders (you) get little or nothing. You must model out different exit scenarios to understand what your rollover equity is actually worth. Negotiating the percentage of your rollover is critical—it’s a direct trade-off between immediate cash and potential future upside (and risk).

The Overlooked R&D Tax Credit for Your Skincare Line

Most dermatologists think the Research & Development (R&D) tax credit is reserved for biotech firms and software companies. This is a costly misconception. Many activities happening right inside your practice likely qualify under IRC Section 41, and you could be leaving tens of thousands of dollars on the table every year.

The credit isn’t just for inventing a new molecule. It applies to developing new or improved “business components,” which can be a product, process, technique, or software. Here’s what this looks like in a dermatology practice:

• Proprietary Skincare Products: Are you working with a compounding pharmacy to develop a unique formulation for a cosmetic cream or a new acne treatment? The costs associated with staff time, supplies, and testing for that formulation process can qualify.
• New Clinical Processes: Are you developing and testing a new protocol for a laser or energy-based device to improve outcomes or reduce side effects? Documenting the systematic trial-and-error process is key.
• Internal Software: Did you hire a developer to build a custom module for your EMR to better track outcomes for aesthetic patients or to manage your Mohs lab workflow? The wages for those involved (including your own time spent directing the project) and contractor fees can be included in the R&D calculation.

The key is the “process of experimentation.” You must be trying to eliminate uncertainty about the capability, method, or appropriate design of the new product or process. Most of us are tinkering constantly. We call it “improving patient care,” not “research and development.” The IRS, however, might see it differently, and that’s a good thing for your bottom line. The trap is a lack of documentation. You must keep contemporaneous records of the projects, the technical challenges you were trying to solve, and the expenses incurred. A specialized accounting firm can help perform an R&D tax credit study to identify these activities and claim the credit retroactively for up to three years.

Boosting Your Valuation: Understanding EBITDA Multiples

If you’re planning to sell your practice one day, you need to start thinking like a buyer today. Private equity firms value your practice based on a multiple of its EBITDA—Earnings Before Interest, Taxes, Depreciation, and Amortization. It’s a proxy for your practice’s cash flow and profitability.

A practice with $1 million in EBITDA might sell for 8x EBITDA ($8 million), while another with the same EBITDA might command a 12x multiple ($12 million). That $4 million difference comes down to the *quality* and *predictability* of your earnings. Buyers pay a premium for businesses that are less risky and have clear growth paths. Here are the key drivers that move your multiple up:

1. Recurring Revenue: A patient who comes in for a one-time Botox injection is valuable. A patient signed up for a “skin health” membership that includes quarterly treatments, product discounts, and an annual skin check is far more valuable. Memberships, subscriptions, and other forms of recurring revenue are highly prized because they make future cash flows more predictable.
2. Diversified Provider Base: A practice where 80% of the revenue is generated by the founding physician is a high-risk investment. What happens if that physician retires or gets sick? A practice with multiple productive dermatologists, PAs, and aestheticians has a much lower concentration risk and will command a higher multiple.
3. Ancillary Services & Retail: Strong retail sales of skincare products and a robust suite of cash-pay aesthetic services demonstrate a diversified revenue stream that is not dependent on insurance reimbursement. This is a major value driver.
4. Efficient Operations: Demonstrating clean books, efficient billing and collections, and well-managed overhead shows a potential buyer that the practice is a well-oiled machine, not a fixer-upper.

The trap is focusing solely on top-line revenue. A high-revenue practice with bloated overhead and unpredictable cash flow will get a lower multiple than a slightly smaller practice with lean operations and sticky, recurring patient revenue. Knowing what buyers value allows you to optimize your practice for maximum enterprise value years before you plan to sell. To do this right, you need a team that understands the nuances of medical practice accounting, which is why working with a physician-focused CPA is so critical.

Supercharging Deductions with Cost Segregation Studies

For practice owners who also own their medical office building, a cost segregation study is one of the most powerful tax strategies available. When you buy a commercial property, the IRS generally requires you to depreciate the building over a 39-year straight-line schedule. That means you get to deduct 1/39th of the building’s value each year. It’s a slow, steady trickle of tax savings.

A cost segregation study shatters that timeline. It’s an engineering-based analysis that dissects the building’s components and reclassifies them into shorter-lived asset classes. Instead of one big 39-year asset, you break it down:

• Land Improvements (15-year property): Parking lots, landscaping, sidewalks.
• Personal Property (5- or 7-year property): Specialty electrical wiring for medical equipment, dedicated plumbing for exam rooms, decorative fixtures, carpeting, and cabinetry.

By reclassifying, say, 25% of a $2 million building’s cost basis ($500,000) from 39-year property to 5-year property, you can accelerate those deductions into the first few years of ownership. Even better, these shorter-lived assets are often eligible for 100% bonus depreciation (though this is phasing down), allowing you to potentially deduct the entire $500,000 in the first year. This creates a massive paper loss that can offset your active practice income, dramatically lowering your current tax bill.

The trap is assuming your regular accountant will handle this. A true cost segregation study must be performed by a specialized engineering firm that can defend its classifications under IRS scrutiny. It’s not just an accounting gimmick; it’s a detailed analysis of construction documents and an on-site inspection. For physicians with a real estate portfolio, this strategy, especially when combined with Real Estate Professional Status (REPS) for a spouse, can be a game-changer. You can use a real estate investing calculator to model the potential impact of accelerated depreciation on your cash flow and returns.

The financial life of a dermatologist is a complex interplay of clinical income, business ownership, and investment strategy. Each of these areas—from structuring a practice sale to optimizing your real estate deductions—requires a level of planning far beyond standard tax preparation. By understanding these specific levers, you can take control of your financial future and ensure the rewards of your hard work are maximized.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 7, 2026